The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

Employers have the opportunity to lead by example: to stop treating obesity as invisible and start addressing it as the ...

South Carolina Medicaid approved GLP-1s to treat obesity, placing it among the few state programs covering the drugs. But ...

As of late 2024, only 14 state Medicaid programs cover GLP-1 drugs like Wegovy, Saxenda, or Zepbound for the treatment of obesity. These states are: California, Connecticut, Indiana, Maryland, ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Medicare covers GLP-1s to treat diabetes and some other health conditions, including obstructive sleep apnea and cardiovascular disease, but not obesity. In early April, the Trump administration ...

The drug also has FDA approval as a weight loss and weight management medication for certain people with obesity. Medicare Part D prescription drug plans may cover Zepbound when a doctor ...

A microsimulation model projected Medicare expenditures to increase $47.7 billion over 10 years with obesity drug coverage. Net health costs could be influenced by price changes, drug uptake and ...